Prentiss Smith & CO Inc Regeneron Pharmaceuticals, Inc. Transaction History

Prentiss Smith & CO Inc

  • $142 Million
  • Q1 2024

A detailed history of Prentiss Smith & CO Inc transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Prentiss Smith & CO Inc holds 3,545 shares of REGN stock, worth $3.73 Million. This represents 2.41% of its overall portfolio holdings.

Number of Shares
3,545
Previous 3,656 3.04%
Holding current value
$3.73 Million
Previous $3.21 Million 6.26%
% of portfolio
2.41%
Previous 2.39%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 30, 2024
SELL
$902.69 - $993.35 $100,198 - $110,261
-111 Reduced 3.04%
3,545 $3.41 Million
Q4 2023

Feb 02, 2024
SELL
$775.18 - $881.7 $1.38 Million - $1.57 Million
-1,779 Reduced 32.73%
3,656 $3.21 Million
Q3 2023

Oct 24, 2023
SELL
$692.45 - $844.37 $105,944 - $129,188
-153 Reduced 2.74%
5,435 $4.47 Million
Q2 2023

Aug 02, 2023
SELL
$700.03 - $830.35 $11,900 - $14,115
-17 Reduced 0.3%
5,588 $4.02 Million
Q1 2023

Apr 28, 2023
SELL
$680.49 - $826.97 $44,912 - $54,580
-66 Reduced 1.16%
5,605 $4.61 Million
Q4 2022

Jan 31, 2023
SELL
$705.89 - $766.39 $160,942 - $174,736
-228 Reduced 3.87%
5,671 $4.09 Million
Q3 2022

Oct 21, 2022
SELL
$573.97 - $724.32 $84,947 - $107,199
-148 Reduced 2.45%
5,899 $4.06 Million
Q2 2022

Aug 12, 2022
SELL
$548.35 - $738.84 $70,737 - $95,310
-129 Reduced 2.09%
6,047 $3.58 Million
Q1 2022

May 09, 2022
SELL
$595.12 - $698.43 $3.35 Million - $3.93 Million
-5,634 Reduced 47.71%
6,176 $4.31 Million
Q4 2021

Jan 28, 2022
BUY
$543.48 - $670.97 $177,717 - $219,407
327 Added 2.85%
11,810 $7.46 Million
Q3 2021

Oct 19, 2021
SELL
$574.03 - $680.96 $5,740 - $6,809
-10 Reduced 0.09%
11,483 $6.95 Million
Q2 2021

Jul 15, 2021
SELL
$472.8 - $558.54 $118,672 - $140,193
-251 Reduced 2.14%
11,493 $6.42 Million
Q1 2021

Jun 21, 2021
BUY
$446.73 - $548.2 $2.2 Million - $2.69 Million
4,916 Added 72.0%
11,744 $5.56 Million
Q4 2020

Feb 03, 2021
SELL
$478.3 - $607.98 $432,383 - $549,613
-904 Reduced 11.69%
6,828 $3.3 Million
Q3 2020

Nov 02, 2020
SELL
$544.75 - $658.21 $77,354 - $93,465
-142 Reduced 1.8%
7,732 $4.33 Million
Q2 2020

Jul 13, 2020
BUY
$493.32 - $643.92 $2,959 - $3,863
6 Added 0.08%
7,874 $4.91 Million
Q1 2020

Apr 29, 2020
SELL
$336.18 - $494.43 $2.77 Million - $4.07 Million
-8,229 Reduced 51.12%
7,868 $3.84 Million
Q4 2019

Jan 21, 2020
SELL
$274.13 - $376.51 $108,281 - $148,721
-395 Reduced 2.4%
16,097 $6.04 Million
Q3 2019

Nov 06, 2019
BUY
$273.46 - $318.39 $16,954 - $19,740
62 Added 0.38%
16,492 $4.58 Million
Q2 2019

Jul 19, 2019
BUY
$299.6 - $414.82 $4.92 Million - $6.82 Million
16,430 New
16,430 $5.14 Million
Q1 2019

Jul 01, 2019
SELL
$372.08 - $439.57 $2.59 Million - $3.06 Million
-6,951 Closed
0 $0
Q4 2018

Jan 15, 2019
BUY
$335.82 - $403.04 $25,858 - $31,034
77 Added 1.12%
6,951 $2.6 Million
Q3 2018

Oct 23, 2018
SELL
$351.14 - $408.51 $1.58 Million - $1.84 Million
-4,494 Reduced 39.53%
6,874 $2.78 Million
Q2 2018

Jul 19, 2018
SELL
$284.6 - $344.99 $2.39 Million - $2.89 Million
-8,385 Reduced 42.45%
11,368 $3.92 Million
Q1 2018

Apr 20, 2018
BUY
$315.82 - $393.78 $2.23 Million - $2.78 Million
7,057 Added 55.58%
19,753 $6.8 Million
Q4 2017

Feb 13, 2018
BUY
$358.63 - $469.95 $4.22 Million - $5.53 Million
11,765 Added 1263.69%
12,696 $4.77 Million
Q3 2017

Oct 23, 2017
BUY
$431.38 - $504.0 $401,614 - $469,224
931
931 $416,000

Others Institutions Holding REGN

# of Institutions
1,424
Shares Held
82.1M
Call Options Held
835K
Put Options Held
1.46M
View Full List

About REGENERON PHARMACEUTICALS, INC.

REGN Quotes by TradingView
  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $113B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Prentiss Smith & CO Inc Portfolio

Follow Prentiss Smith & CO Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prentiss Smith & CO Inc, based on Form 13F filings with the SEC.

News

Stay updated on Prentiss Smith & CO Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email